SAN DIEGO -- Aethlon Medical, Inc. (OTCBB:AEMD), a pioneer in developing medical devices to treat infectious disease, announced today that researchers have documented the Aethlon Hemopurifier[R] is able to remove the immunosuppressive activity normally found in the fluid of cancer patients. Aethlon recently discovered the Hemopurifier[R] efficiently captures tumor secreted exosomes that inhibit the ability of the immune system to combat cancer. In follow-on studies, led by Dr. Douglas Taylor at the University of Louisville, it has now been demonstrated that the capture of exosomes by the Hemopurifier[R] does result in reversing immunosuppressive activity. Dr. Taylor is a recognized authority on the causative effects of immune suppression in cancer patients. He is credited with the initial characterization of exosomes and is a leading peer reviewed author on the subject.
"Based on emerging data, we envision the Hemopurifier[R] will become a treatment standard that enhances the benefit of therapies administered to those who suffer from cancer," stated James A. Joyce, Chairman and CEO of Aethlon Medical.
In the studies, the Aethlon Hemopurifier[R] completely removed the immunosuppressive activity normally found in the ascites fluid of ovarian cancer patients. Immunosuppressive activity in ovarian cancer patients is known to correlate with disease progression and long-term survival. The studies measured the expression of two biological markers required for T-cell activation. The markers, Jak-3 kinase and CD3-zeta chain expression are respectively required for interleukin (cytokine) activation of cell proliferation and T-cell receptor mediated activation. Both markers are highly expressed in T-cell lines. When cells were subjected to ovarian cancer ascites fluid, both markers were consistently absent. However, the circulation of the same ascites fluid through the Aethlon Hemopurifier[R], allowed the expression of both biological markers necessary to activate the immune response.
SAN DIEGO -- Aethlon Medical, Inc. (OTCBB:AEMD) announced today that it has exercised an option to exclusively license a pending patent entitled "Method to Inhibit Proliferation and Growth of Metastases" from The Trustees of Boston University. The license provides a rapid development strategy for new cancer therapies by uniting drug agents that inhibit the spread of cancer related metastases, with filtration techniques already proven in the Aethlon Hemopurifier[R]. The resulting devices would inhibit tumor growth by reducing the presence of circulating growth factors without interfering with surgical wound healing or the recovery of tissue injured by radiation therapy. While the market for anti-growth factor drug agents exceeds $5 billion, there remains a significant unmet clinical need, as these drug agents may not be indicated for use in conjunction with surgical procedures or radiation treatment as they inhibit wound healing and tissue recovery.
"The development of devices that capture growth factors that cause the spread of cancer reinforces our long-term strategy to build a cohesive product pipeline by leveraging filtration techniques evolved in the development of our Hemopurifier[R] in combination with affinity agents that allow us to pursue new market opportunities," stated James A. Joyce, Chairman and CEO of Aethlon Medical.
The Aethlon Hemopurifier[R] is a first-in-class medical device that provides real-time therapeutic filtration of infectious viruses and immunosuppressive particles from circulation. The initial demonstration of safety in human combined with extensive supporting data from pre-clinical in vitro studies have positioned the Hemopurifier[R] to be a leading broad-spectrum treatment candidate against drug and vaccine resistant infectious diseases. The Hemopurifier[R] has also demonstrated in vitro effectiveness in capturing immunosuppressive proteins that are secreted by tumors and shed by viruses.
"As we continue to progress the
infectious disease applications of our Hemopurifier(R), the Journal of
Translational Medicine publication recognizes and reinforces the additional
potential of the Hemopurifier(R) within the $43 billion
cancer
Aethlon previously disclosed that
researchers discovered that the Hemopurifier(R) is effective in capturing
exosomes that are released by solid tumors, lymphomas, and leukemia.
Exosomes induce T-cell apoptosis (programmed cell death), and block T-cell
signaling, proliferation, and cytokine production. High concentrations of
circulating exosomes correlate with reduced T-cell production and tumor
progression in cancer patients. In studies led by Dr. Douglas Taylor at the
University of Louisville, 60% of circulating exosomes were removed from the
blood of
ovarian
click browser BACK ARROW to return